Patent intelligence · US
US 12257224
Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker
Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker
Patent details — US 12257224
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 25, 2025
- Expiration
- Mar 20, 2045
- Applicant
- Milestone Pharmaceuticals Inc.
- Claims
- 22
- CPC classes
- A61K, A61K31/277, A61K31/7048, A61K31/7076
Quick answer
US 12257224 (Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker) is held by Milestone Pharmaceuticals Inc.. Status: granted. Granted Mar 25, 2025. Expires Mar 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Milestone Pharmaceuticals Inc.
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K31/277, A61K31/7048, A61K31/7076, A61K45/06, A61K47/183
More from Milestone Pharmaceuticals Inc.
Related pharmaceutical patents in our USPTO index.
-
US 10632255
Drug infusion device
granted -
US 10308609
Bicyclic compounds
granted -
US 10251851
Bicyclic analgesic compounds
granted -
US 10117848
Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
granted -
US 10010524
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted -
US 10010523
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted -
US 10010522
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted
Frequently asked questions
What is US patent 12257224?
US 12257224 (Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker) is held by Milestone Pharmaceuticals Inc.. Status: granted. Granted Mar 25, 2025. Expires Mar 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12257224?
Milestone Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 12257224 expire?
Our index shows an expiration date of Mar 20, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.